,"CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)  shares in Millions, $ in Millions",12 Months Ended,12 Months Ended,12 Months Ended
,"CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)  shares in Millions, $ in Millions","Dec. 31, 2018","Dec. 31, 2017","Dec. 31, 2016"
0,Revenues:,,,
1,Revenues,"$ 6,710.8","$ 5,872.2","$ 4,860.4"
2,Expenses:,,,
3,Research and development,2186.1,2075.1,2052.3
4,"Selling, general, and administrative",1556.2,1320.4,1177.7
5,Total expenses,4176.4,3792.6,3529.7
6,Income from operations,2534.4,2079.6,1330.7
7,Other income (expense):,,,
8,"Other income (expense), net",47.3,24.0,6.3
9,Interest expense,(28.2),(25.1),(7.2)
10,Total other income (expense),19.1,(1.1),(0.9)
11,Income before income taxes,2553.5,2078.5,1329.8
12,Income tax expense,(109.1),(880.0),(434.3)
13,Net income,"$ 2,444.4","$ 1,198.5",$ 895.5
14,Net income per share - basic (in dollars per share),$ 22.65,$ 11.27,$ 8.55
15,Net income per share - diluted (in dollars per share),$ 21.29,$ 10.34,$ 7.70
16,Weighted average shares outstanding - basic (in shares),107.9,106.3,104.7
17,Weighted average shares outstanding - diluted (in shares),114.8,115.9,116.3
18,Statements of Comprehensive Income,,,
19,Net income,"$ 2,444.4","$ 1,198.5",$ 895.5
20,"Other comprehensive income (loss), net of tax:",,,
21,Unrealized (loss) gain on marketable securities,(7.0),12.7,(21.4)
22,Unrealized gain on cash flow hedges,0.7,0.8,0.0
23,Comprehensive income,2438.1,1212.0,874.1
24,Product,,,
25,Revenues:,,,
26,Revenues,4106.2,3718.5,3338.4
27,Expenses:,,,
28,Cost of goods sold,180.0,202.5,194.6
29,Collaboration and contract manufacturing,,,
30,Expenses:,,,
31,Cost of goods sold,254.1,194.6,105.1
32,"Sanofi | Product and service, other",,,
33,Revenues:,,,
34,Revenues,1111.1,877.2,658.7
35,"Bayer | Product and service, other",,,
36,Revenues:,,,
37,Revenues,1076.7,938.1,744.3
38,"Other | Product and service, other",,,
39,Revenues:,,,
40,Revenues,$ 416.8,$ 338.4,$ 119.0
